A new Wharton study explains why stock returns aren’t random. Correlation neglect causes market overreaction, momentum, and reversals investors consistently misprice.
Bristol-Myers Squibb & Co. BMY on Monday released topline results from a phase 2 study evaluating Reblozyl for anemia in ...
CervoMed's stock surged more than 400% after interim data showed significant improvement with a new batch of neflamapimod in treating Dementia with Lewy Bodies. The recent interim readout deserves ...
In a recent study published in Engineering, a team of Chinese researchers has uncovered a startling correlation between stock market volatility and the risk of major adverse cardiovascular events ...
Thursday, NuCana plc (NASDAQ:NCNA) announced that the NuTide:323 study is being discontinued following a pre-planned initial analysis and recommendation from the NuTide:323 Study Steering Committee.
Immunovant, Inc. IMVT shares gained 10.8% on Wednesday after the company announced new six-month off-treatment results from a proof-of-concept study evaluating its investigational candidate, ...
Shares of Arcus Biosciences, Inc. RCUS, a clinical-stage biopharmaceutical company, declined 14.4% following the announcement that its late-stage STAR-221 study was discontinued for futility. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results